A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy, Ajay K. Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob P. Laubach, Cristina Gasparetto, Asher Chanan‐Khan, Mark Hertzberg, Mark DeMario, E. Nueesch, Evelyne Chesné, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Hearn Jay Cho
Topics & Concepts
Multiple myelomaMedicineMaximum tolerated doseInternal medicineOncologyClinical trialProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways